

NHS South Yorkshire ICB Medicines Optimisation Quality Improvement/Incentive Scheme QIPP Reviews Supporting Information v1.7

QIPP reviews form part of component C within the Medicines Optimisation Quality Improvement/Incentive Scheme 2026-27. Practices are required to review a selection of medicines identified within the South Yorkshire ICB QIPP work programme as suitable for switching to lower cost alternative formulations or products, in line with the requirements of the scheme.

Decision support software (OptimiseRx) will be updated, where applicable, to support these switches by prompting prescribers within clinical systems.

Patients prescribed the identified medication should be reviewed, and where clinically appropriate, offered a change in therapy.

Practice system searches will be made available for the drugs in the following groups:

- Brand to generic switches
- Formulation changes
- Change of brand
- Deprescribing review
- Drug switches

Brand to generic switches

Branded Product	Strength	Proposed switch to
Bondronat® 50mg tablets	50mg	Ibandronic acid 50mg tablets
Circadin® MR tablets	2mg	Melatonin 2mg MR tablets
Dymista® nasal spray	137mcg/dose/50mcg/dose	Fluticasone propionate /azelastine hydrochloride nasal spray
Flomister® nasal spray	137mcg/dose/50mcg/dose	Fluticasone propionate /azelastine hydrochloride nasal spray
Ganfort® eye drops	0.3mg/ml/5mg/ml	Bimatoprost /timolol eye drops
Losec® GR capsules	All	Omeprazole GR capsules
Nexium® GR tablets	All	Esomeprazole GR tablets
Utrogestan® capsules (oral)	100mg	Progesterone micronised 100mg capsules
Vimpat® tablets	All	Lacosamide tablets
Xalacom® eye drops	50mcg/ml 5mg/ml	Latanoprost/timolol eye drops

Formulation Changes

Product	Strength	Proposed switch to	Additional Information
Co-codamol capsules	8/500	Co-codamol tablets	
Domperidone oral suspension	1mg/ml	Epzit® 10mg orodisperible tablets	
Dorzolamide eye drops 0.2ml Unit Dose Preservative Free	20mg/ml	Dorzolamide 20mg/ml eye drops preservative free 5ml multidose bottle	
Doxazosin tablets	8mg	TWO 4mg doxazosin tablets in place of ONE 8mg doxazosin tablet	
Estriol vaginal cream with applicator	0.01%	Estriol 1mg/ml 0.1% cream	
Glyceryl trinitrate aerosol SL spray	400 micrograms/dose	Glyceryl trinitrate 400 micrograms/dose pump sublingual spray	
Liothyronine tablets	10 micrograms	Liothyronine capsules	
Liothyronine capsules	20 micrograms	Liothyronine tablets	
Melatonin MR tablets (Slenyto® MR tablets)	1mg and 5mg	Melatonin 2mg MR tablets	Will not be a suitable switch for every patient. Consider as an option in patients who are taking even numbered milligram doses (e.g. 2mg, 4mg, 6mg, 8mg, 10mg), where the same total dose can be delivered using one or more 2mg MR tablets. SY Melatonin Shared Care Protocol
Memantine orodispersible tablets	10mg and 20mg	Memantine tablets	
Nebivolol tablets	1.25mg	Nebivolol 2.5mg tablets (half a tablet)	Prescribe half a 2.5mg tablet. Will not be a suitable switch for every patient.

Omeprazole oral suspension SF	10mg/5ml and 20mg/5ml	Omeprazole dispersible GR tablets	Only where doses can be safely given using a quarter, half or full dispersible tablet. Sheffield Children's Hospital guideline 2054v1.1 PPIs H2 Antagonists Guideline (1).pdf
Perindopril arginine tablets	All	Perindopril erbumine tablets	Perindopril arginine 2.5mg to perindopril erbumine 2mg Perindopril arginine 5mg to perindopril erbumine 4mg NHS England » Items which should not routinely be prescribed in primary care: policy guidance
Riluzole tablets	50mg	Emlif® (riluzole) orodispersible films	
Risperidone orodispersible tablets	All	Risperidone 1mg/ml oral solution	If the oral solution is not clinically appropriate, consider whether ONE risperidone orodispersible 4mg tablet can be changed to TWO risperidone orodispersible 2mg tablets
Rivastigmine capsules	6mg	TWO 3mg rivastigmine capsules in place of ONE 6mg rivastigmine capsule	No longer savings
Rosuvastatin capsules	All	Rosuvastatin tablets	
Sertraline tablets	25mg	Sertraline 50mg tablets (half a tablet)	Prescribe half a 50mg tablet. Will not be a suitable switch for every patient
Spironolactone tablets	12.5mg	Spironolactone 25mg tablets (half a tablet)	Prescribe half a 25mg tablet. Will not be a suitable switch for every patient
Tamsulosin modified release tablets	400 micrograms	Tamsulosin modified release capsules	
Ursodeoxycholic acid tablets	500mg	Ursodeoxycholic acid capsules	
Zolmitriptan tablets	2.5mg	Zolmitriptan 2.5mg orodispersible tablets	

Change of brand switch

Product	Strength	Proposed switch to	Additional Information
Aveeno® cream or Zeroveen® cream		Epimax® oatmeal cream	
Balneum Plus cream or E45 Itch Relief cream		ImuDERM® emollient	Review suspended as an individual patient review is required
Buprenorphine <u>weekly</u> patches including brands with a higher acquisition cost e.g. Butec® patches, BuTrans® patches	5 micrograms/hour 10 micrograms/hour 15 micrograms/hour 20 micrograms/hour	Lower acquisition cost brands include Bunov® or Sevodyne® patches	Refer to place-based formulary/guidance for further information. Barnsley & Rotherham-Sevodyne® Sheffield & Doncaster-Bunov®
Buprenorphine <u>twice weekly</u> patches including brands with a higher acquisition cost e.g. Transtec® patches	35 micrograms/hour 52.5micrograms/hour 70 micrograms/hour	Lower acquisition cost brands include Bupeaze® (replace patch every 4 days) or Hapoctasin® (replace patch every 3 days-see additional information)	Refer to place-based formulary/guidance for further information. Hapoctasin® is contraindicated in patients who are allergic to peanuts or soya.
Cetranab® or Zerobase® 11% or E45® cream		Epimax® Original Cream	
Clenil® Modulite Inhaler	50mcg/dose 100mcg/dose 250mcg/dose	Soprobec® Inhaler	
Denosumab pre-filled syringes (Prolia®)	60mg/ml	Stoboclo® 60mg/ml Injection	SY ICB Denosumab Shared Care Protocol SY Biosimilar Medicines Position Statement
Donepezil orodispersible tablets S/F	5mg 10mg	Apozyl® orodispersible tablets	
Doublebase® gel		Epimax® Isomol Gel	
Felodipine MR tablets	10mg	Delofine® XL 10mg tablets	
Fentanyl patches	All	Opiodur® patches	
Macrogol 3350 oral powder 8.5g sachets (Transisoft®)		Macrogol compound oral powder sachets NPF sugar	Refer to place-based formulary/guidance for further information.

The 8.5g sachets have a high acquisition cost £217.46 x 28 sachets (Drug Tariff June 2026)		free (prescribed generically) or Laxido® or Cosmocol®	Barnsley – Laxido®, Sheffield – Cosmocol®, Doncaster - Laxido®, Rotherham - Laxido®
Oxycodone capsules (<u>immediate release</u>) / OxyNorm® capsules	All	Shortec® capsules	
Oxycodone <u>modified release</u> tablets (including brands with a high acquisition cost such as Longtec® MR Tablets, Oxycontin® MR Tablets)	All	Oxypro® MR tablets	
Phosphate enema long and standard tubes		Cleen® Ready-to-Use 133ml enema	
Pramipexole modified release tablets	1.57mg, 2.1mg, 2.62mg, 3.15mg	Pipexus® MR tablets	
Proctosedyl® and cinchocaine/hydrocortisone ointment and suppositories		Scheriproct® ointment and suppositories	
Simple eye ointment		Xailin® Night eye ointment P/F	
Sodium picosulfate oral solution S/F	5mg/5ml	Dulcolax® Pico Adult 5mg/5ml liquid	Dulcolax® Pico Adult liquid contains alcohol and is licensed for use in patients ≥18 years
Spiriva® inhalation powder capsules and Tiotropium inhalation powder capsules	18mcg	Tiogiva® 18mcg inhalation powder capsules	
Venlalic® XL, ViePax® XL, Vensir® XL, Venlasov® XL, Efexor XL, Sunveniz® XL, Venlafaxine MR capsules and tablets	150mg MR	Vencarm® XL 150mg MR capsules	

De-prescribing review

Product	Additional Information
Colgate Duraphat Fluoride & Fluoritop HF Fluoride Toothpaste	Review in line with SYICB Dental Position Statement: SY ICB Medicines Optimisation

Drug switch review

Product	Proposed switch to	Additional Information
---------	--------------------	------------------------

Nizatidine 150mg and 300mg capsules	Famotidine tablets (20mg and 40mg tablets available)	H2-receptor antagonists Prescribing information Dyspepsia - proven GORD CKS NICE
-------------------------------------	--	--